id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2635082,eabbdcc0-290a-4ebf-a1fb-5cdfd54f9bbb,Q2,"TAUZIN CONSULTANTS, LLC",400671007,SCILEX HOLDING COMPANY,2021,second_quarter,HCR,"Issues related to fair competition, the generic drug market, drug costs, pain management, non-opioid alternatives, and prior authorization. Also issues related to COVID-19.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-07-12T10:50:31.850000-04:00
2635083,eabbdcc0-290a-4ebf-a1fb-5cdfd54f9bbb,Q2,"TAUZIN CONSULTANTS, LLC",400671007,SCILEX HOLDING COMPANY,2021,second_quarter,MMM,"Issues related to fair competition, the generic drug market, drug costs, pain management, non-opioid alternatives, and prior authorization. Also issues related to COVID-19.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2021-07-12T10:50:31.850000-04:00